Summit Therapeutics (SUMM)

 

Latest News

Summit Therapeutics plc : Miscellaneous

Summit to present at Duchenne Conference

Summit Therapeutics has confirmed that new preclinical data shows a positive effect of utrophin modulation on improvin...

Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne

A statement giving an update on research (e.g. clinical trials)

Summit inks revenue sharing agreement with Wellcome Trust

Summit Therapeutics confirmed that the Company has entered into an equity and revenue sharing agreement with the W...

All News

DateHeadlineSource
16-11-17Summit Therapeutics plc : MiscellaneousRNS
09-11-17Summit to present at Duchenne ConferenceStockMarketWire
09-11-17Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action DuchenneRNS
06-11-17Summit inks revenue sharing agreement with Wellcome TrustStockMarketWire
06-11-17Summit Therapeutics Announces Revenue Sharing Agreement with Wellcome TrustRNS
25-10-17Summit Therapeutics plc : Grant of share optionsRNS
23-10-17Summit Therapeutics plc : Block listing applicationRNS
13-10-17Summit Therapeutics plc : Holding(s) in CompanyRNS
09-10-17Summit highlights Microbiome Preservation during Ridinilazole treatmentStockMarketWire
09-10-17Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017RNS
05-10-17Summit Therapeutics plc : Exercise of OptionsRNS
04-10-17Summit to present at conference in Saint-MaloStockMarketWire
04-10-17Summit Highlights DMD Biomarker Validation Data at 22nd WMS CongressRNS
03-10-17Summit Therapeutics plc : Exercise of OptionsRNS
02-10-17Summit to host R&D dayStockMarketWire
02-10-17Summit Therapeutics to Host R&D Day 11 October 2017RNS
29-09-17Summit Therapeutics plc : Exercise of Share OptionsRNS
29-09-17Best AIM companies of 2017 Interactive Investor
28-09-17Summit Therapeutics plc : Exercise of Share OptionsRNS
25-09-17Summit joins cTAPStockMarketWire
25-09-17Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMDRNS
21-09-17Summit Therapeutics plc : Holding(s) in CompanyRNS
20-09-17Summit Therapeutics plc : Holding(s) in CompanyRNS
18-09-17Summit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before ExpensesRNS
15-09-17Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment OptionRNS
14-09-17Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before ExpensesRNS
11-09-17Summit awarded Barda contract worth up to $62mStockMarketWire
11-09-17Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDIRNS
05-09-17Summit announces positive ridinilazole trial resultsStockMarketWire
05-09-17Summit Therapeutics plc : Positive Top-line Phase 2 ResultsRNS
31-08-17Summit Therapeutics plc : Half-yearly reportRNS
25-08-17Summit Therapeutics plc : Notice of ResultsRNS
03-08-17Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceRNS
31-07-17Summit Therapeutics plc : Total voting rightsRNS
19-07-17Summit Therapeutics plc : Grant of Share Options and Restricted Stock UnitsRNS
18-07-17Summit Therapeutics plc : Result of AGMRNS
28-06-17Summit Therapeutics plc : Grant of Share OptionsRNS
28-06-17Summit Therapeutics plc : Exercise of Share OptionsRNS
22-06-17Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS CongressRNS
16-06-17Four AIM shares for a post-election worldInteractive Investor

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account